A detailed history of Allspring Global Investments Holdings, LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Allspring Global Investments Holdings, LLC holds 103,842 shares of PTGX stock, worth $4.82 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
103,842
Previous 428 24162.15%
Holding current value
$4.82 Million
Previous $14,000 33228.57%
% of portfolio
0.01%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$33.72 - $47.33 $3.49 Million - $4.89 Million
103,414 Added 24162.15%
103,842 $4.67 Million
Q2 2024

Jul 26, 2024

SELL
$24.66 - $34.8 $38,025 - $53,661
-1,542 Reduced 78.27%
428 $14,000
Q1 2024

Apr 18, 2024

SELL
$21.79 - $32.15 $12,267 - $18,100
-563 Reduced 22.23%
1,970 $56,000
Q4 2023

Jan 25, 2024

SELL
$14.05 - $23.44 $83,920 - $140,007
-5,973 Reduced 70.22%
2,533 $58,000
Q3 2023

Oct 27, 2023

BUY
$16.68 - $23.66 $141,880 - $201,251
8,506 New
8,506 $141,000
Q2 2023

Jul 18, 2023

SELL
$18.02 - $29.36 $867,392 - $1.41 Million
-48,135 Reduced 21.52%
175,529 $4.85 Million
Q1 2023

Apr 13, 2023

BUY
$10.78 - $25.38 $2.35 Million - $5.53 Million
217,761 Added 3688.99%
223,664 $5.14 Million
Q4 2022

Jan 23, 2023

SELL
$7.36 - $11.17 $42,570 - $64,607
-5,784 Reduced 49.49%
5,903 $64.4 Million
Q3 2022

Oct 26, 2022

BUY
$7.86 - $11.71 $10,807 - $16,101
1,375 Added 13.33%
11,687 $98,000
Q2 2022

Jul 25, 2022

SELL
$7.06 - $25.52 $119,977 - $433,686
-16,994 Reduced 62.24%
10,312 $81,000
Q1 2022

May 02, 2022

BUY
$23.34 - $36.08 $45,162 - $69,814
1,935 Added 7.63%
27,306 $646,000
Q4 2021

Jan 28, 2022

BUY
$17.63 - $37.1 $447,290 - $941,264
25,371 New
25,371 $867,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.28B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Allspring Global Investments Holdings, LLC Portfolio

Follow Allspring Global Investments Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allspring Global Investments Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Allspring Global Investments Holdings, LLC with notifications on news.